BCL2 and lymphoma: The development and validation of a highly specific rabbit monoclonal antibody for myc has made a major impact in lymphoma diagnosis where the combination of MYC and BCL2 overexpression as determined by immunohistochemistry alone has been used to define a poor prognosis group of B-cell non Hodgkin lymphoma known as double hit lymphomas.